Skip to main content
TipRanks
Go Ultimate75% OFF

Hikal Limited (HIKAL) AI Stock Analysis

2 Followers
IN:HIKAL

Hikal Limited

(NSE:HIKAL)

Select Model
Rating:53Neutral
Price Target:INR 220.00â–²(1.52% Upside)
Action:reiterated
Date:09/08/26

Moderate financial performance from balance sheet strength amid revenue and profit volatility is the main driver; supportive technical trends above moving averages add lift while negative P/E heavily weighs on valuation.

Positive Factors
Diversified specialty-chemicals platformExposure to both pharmaceuticals and crop protection, combined with development, manufacturing, process scale-up and CDMO capabilities, gives Hikal multiple routes to participate in customer programs. Serving global innovators and generic manufacturers can support a durable, diversified commercial base.
Negative Factors
Recent profitability deteriorationThe shift to a net loss materially weakens earnings quality and reduces the company’s ability to fund growth from internally generated profits. Unless margins recover or operating costs improve, continued losses could erode equity, constrain investment capacity, and increase balance-sheet pressure.

Hikal Limited (HIKAL) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%20%IN:HIKAL-4.92%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 27.79B
Dividend Yield
0.28%
Average Volume (3M)
75.40K
Price to Earnings (P/E)
-541.5
Beta (1Y)
1.02
Revenue Growth
8.93%
EPS Growth
-149.51%
Country
India
Employees
3,595
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Hikal Limited Business Overview & Revenue Model

Company Description

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty ch...

Hikal Limited Financial Statement Overview

Summary

Balance sheet stability with improved leverage supports moderate score, offset by volatile revenue, recent net losses, and fluctuating free cash flow.

Income Statement

45Neutral

Balance Sheet

65Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue17.33B17.13B18.60B17.69B20.05B19.26B
Gross Profit6.37B5.17B10.22B9.05B8.62B8.83B
EBITDA1.94B1.48B3.33B2.67B2.60B3.40B
Net Income-338.00M-488.00M908.00M696.02M783.82M1.60B
Balance Sheet
Total Assets023.65B25.29B24.87B23.85B22.13B
Cash, Cash Equivalents and Short-Term Investments138.00M136.00M178.00M181.93M267.30M217.09M
Total Debt06.84B7.65B8.18B7.48B6.75B
Total Liabilities-11.99B11.67B12.67B12.99B12.52B11.45B
Stockholders Equity11.99B11.99B12.62B11.88B11.33B10.68B
Cash Flow
Free Cash Flow1.28B892.00M1.43B-174.80M126.89M204.19M
Operating Cash Flow2.72B2.37B2.80B1.87B3.15B2.94B
Investing Cash Flow-1.46B-1.46B-1.36B-1.74B-2.92B-2.84B
Financing Cash Flow-1.29B-943.00M-1.44B-270.00M-76.80M-55.58M

Hikal Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price216.70

Price Trends

50DMA218.87Negative
100DMA219.41Negative
200DMA204.42Positive

Market Momentum

MACD1.90Negative
RSI50.15Neutral
STOCH55.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HIKAL, the sentiment is Neutral. The current price of 216.70 is above the 20-day moving average (MA) of 213.24, below the 50-day MA of 218.87, and above the 200-day MA of 204.42, indicating a neutral trend. The MACD of 1.90 indicates Negative momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 55.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:HIKAL.

Hikal Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:HIKAL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SUPRIYAIN:SUPRIYA69NeutralINR 50.11B28.27―0.16%23.00%-2.84%
IN:ROSSARIIN:ROSSARI65NeutralINR 23.61B15.49―0.12%19.76%11.74%
IN:WOCKPHARMAIN:WOCKPHARMA57NeutralINR 325.70B79.48――25.70%―
IN:DCALIN:DCAL56NeutralINR 21.91B32.01――-20.86%-34.51%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:HIKALIN:HIKAL53NeutralINR 26.72B-541.45―0.28%8.93%-149.51%
IN:SOLARAIN:SOLARA50NeutralINR 30.50B82.34――27.30%456.80%

* General Sector Average

Performance Comparison

-25%0%25%50%75%IN:HIKALIN:DCALIN:ROSSARIIN:SOLARAIN:SUPRIYAIN:WOCKPHARMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:HIKAL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:HIKALHikal Limited216.70-10.21-4.50%
IN:DCALDishman Carbogen Amcis Ltd.139.75-102.40-42.29%
IN:ROSSARIRossari Biotech Ltd426.25-195.30-31.42%
IN:SOLARASolara Active Pharma Sciences Ltd.634.4565.4511.50%
IN:SUPRIYASupriya Lifescience Limited622.65-141.54-18.52%
IN:WOCKPHARMAWockhardt Limited2004.50673.9550.65%

Hikal Limited Corporate Events

Hikal’s Bengaluru API Plant Secures Swissmedic GMP Nod, Bolstering Global Reach

Oct 30, 2026

Hikal Limited has announced that its active pharmaceutical ingredient facility in Bengaluru has received a Certificate of GMP Compliance from Swissmedic, confirming adherence to European Union–Switzerland mutual recognition standards. This certificat...

Hikal Schedules Analyst and Investor Visit to Pune R&T Centre

Sep 2, 2026

Hikal Limited has scheduled an in-person group meeting for analysts and institutional investors at its Pune research and technology centre on September 4, 2026, starting at 12:00 p.m. IST. The visit will include interactions with company officials, w...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 07, 2026